Urgent.News

600+ sources. One page. See who else covered it.

Editions

Health & Medicine

FDA expands Pluvicto label, making it available to most metastatic prostate cancer patients

The FDA approved Novartis’ radiopharma drug Pluvicto for use alongside hormone therapy, making the drug available to many more patients. The approval nearly doubles the eligible patient population for Pluvicto, according to a Novartis

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Monday 3 August →